About this trial
CAPA-IVM (In Vitro Maturation) technology is an assisted reproductive method offering significant benefits in terms of safety and treatment costs, particularly for high-risk patients. These include individuals with ovarian hyperstimulation syndrome (OHSS), venous thrombosis, ovarian torsion, or polycystic ovary syndrome (PCOS). However, while the live birth rate in the CAPA-IVM group (35.2%) is comparable to conventional IVF (43.2%), the number of good-quality embryos and cumulative clinical pregnancy rates remain lower. Improving the CAPA-IVM culture process, particularly through the addition of growth factors found in follicular fluid, has shown promise in enhancing oocyte quality.
Growth differentiation factor 9 (GDF9) and Bone morphogenetic protein 15 (BMP15) play critical roles in follicular development, with their heterodimer structure demonstrating the most positive effects on cumulus-oocyte complexes (COCs). Recent studies have identified a potent variant, super GDF9, which is \>1000 times more effective than GDF9 and surpasses cumulin, a heterodimeric growth factor. Super GDF9 enhances cumulus cell expansion and oocyte developmental competence, closely mimicking in vivo maturation.
This study investigates the impact of supplementing super GDF9 during CAPA-IVM culture, aiming to improve outcomes of cumulus-oocyte complexes (COCs) from small follicles and ultimately enhance treatment success.
Eligibility criteria
Qualifiers
Women between the ages of 18 and 38 years (both inclusive)
BMI ≤ 32 kg/m2
PCOS women according to the Rotterdam criteria (2003)
Indicating CAPA-IVM treatment.
Disqualifiers
Known endometrioma or grade 3-4 endometriosis according to ASRM classification
Uterine abnormalities
Couples with severe male factor (sperm concentration <5 million/ml, motility < 10%), surgical sperm retrieval.
Previous history of unexplained immature oocytes after IVF treatment
Trial design
Treatments tested in this trial
- Super-GDF9 supplementation during CAPA-IVM
- Conventional CAPA-IVM
Treatment groups
Sponsors and collaborators
Mỹ Đức Hospital
Lead sponsor
Vrije Universiteit Brussel
Collaborator